Literature DB >> 9655294

Technetium-99m methoxyisobutylisonitrile chest imaging of small cell lung carcinoma: relation to patient prognosis and chemotherapy response--a preliminary report.

C H Kao1, S P ChangLai, P U Chieng, T C Yen.   

Abstract

BACKGROUND: The purpose of this preliminary study was to evaluate retrospectively the relation between chemotherapy response and survival time, using technetium-99m methoxyisobutylisonitrile (Tc-99m MIBI) uptake in small cell lung carcinoma (SCLC) to detect the expression of multidrug resistance (mdr)-mediated 170-kDa P-glycoprotein (PgP).
METHODS: Before the administration of chemotherapy (which consisted of cisplatin 25 mg and etoposide 125 mg every day per 3-day course), 15 male patients (ages 54-64 years) with SCLC were enrolled in this study to undergo Tc-99m MIBI chest imaging, including single photon emission computed tomography (SPECT) and planar imaging, for qualitative and quantitative assessments of PgP in their SCLC.
RESULTS: In 12 of 15 cases (80%), SCLC could be detected by visual interpretation of the Tc-99m MIBI chest SPECT images. In 13 of 15 cases (87%), Tc-99m MIBI chest SPECT images (either positive SPECT with good response or negative SPECT with poor response) correctly predicted chemotherapy response. The correlation between tumor uptake ratios obtained by planar images (total counts in the region of interest [ROI] of the tumor divided by total counts in the same size ROI of the contralateral normal lung) and survival days (from the time of SCLC diagnosis to the time of the patient's death) was both positive and good (correlation coefficient=0.83).
CONCLUSIONS: Tc-99m MIBI chest images have the potential to demonstrate mdr-PgP expression in SCLC and to predict patient prognosis and chemotherapy response.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9655294     DOI: 10.1002/(sici)1097-0142(19980701)83:1<64::aid-cncr9>3.0.co;2-e

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Prediction of the response to docetaxel-based chemotherapy for locoregionally advanced nasopharyngeal carcinoma: the role of double-phase (99m)Tc-MIBI SPECT/CT.

Authors:  Chengrun Du; Hongmei Ying; Junjun Zhou; Jinjin Jiang; Chang Liu; Jingyi Chen; Xiaosheng Wang; Chaosu Hu
Journal:  Med Oncol       Date:  2014-01-09       Impact factor: 3.064

2.  To use MIBI or not to use MIBI? That is the question when assessing tumour cells.

Authors:  Jean-Luc Moretti; Nathalie Hauet; Meltem Caglar; Olivier Rebillard; Zeynep Burak
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-07       Impact factor: 9.236

3.  Using technetium-99m methoxyisobutylisonitrile lung single-photon-emission computed tomography to predict response to chemotherapy and compare with P-glycoprotein expression in patients with untreated small cell lung cancer.

Authors:  Sheng-Pin Changlai; Chang-Shu Tsai; Hueisch-Jy Ding; Wen-Tao Huang; Albert Kao; Wu-Huei Hsu
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

4.  ⁹⁹mTc-N4amG: synthesis biodistribution and imaging in breast tumor-bearing rodents.

Authors:  Ning Tsao; Mithu Chanda; Dong-Fang Yu; Hiroaki Kurihara; Yin-Han Zhang; Richard Mendez; David J Yang
Journal:  Appl Radiat Isot       Date:  2012-10-11       Impact factor: 1.513

5.  Predicting early chemotherapy response with technetium-99m methoxyisobutylisonitrile SPECT/CT in advanced non-small cell lung cancer.

Authors:  Tzu-I J Yang; Tjeerd S Aukema; Harm van Tinteren; Sjaak Burgers; Renato Valdés Olmos; Marcel Verheij
Journal:  Mol Imaging Biol       Date:  2009-09-12       Impact factor: 3.488

6.  Synthesis and evaluation of amino acid-based radiotracer 99mTc-N4-AMT for breast cancer imaging.

Authors:  Fan-Lin Kong; Mohammad S Ali; Yinhan Zhang; Chang-Sok Oh; Dong-Fang Yu; Mithu Chanda; David J Yang
Journal:  J Biomed Biotechnol       Date:  2011-04-07

7.  Development of (99m)Tc-N4-NIM for molecular imaging of tumor hypoxia.

Authors:  Mohammad S Ali; Fan-Lin Kong; Alex Rollo; Richard Mendez; Saady Kohanim; Daniel Lee Smith; David J Yang
Journal:  J Biomed Biotechnol       Date:  2012-06-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.